Date: 2018-04-30
Type of information: Private placement
Company: Sangamo Therapeutics (USA - CA)
Investors:
Amount: $230 million
Funding type: private placement
Planned used:
- Sangamo Therapeutics anticipates using the net proceeds from the offering to support its own and its partnered gene therapy, genome editing, cell therapy and gene regulation product candidates and research programs, its manufacturing facilities and other business development activities, as well as for general corporate purposes, including working capital.
Others:
- • On April 30, 2018, Sangamo Therapeutics announced the completion of its previously announced underwritten public offering of 14,156,500 shares of its common stock at a price to the public of $16.25 per share, including 1,846,500 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Sangamo. Including the option exercise, the aggregate gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $230.0 million.
- • On April 25, 2018, Sangamo Therapeutics announced the pricing of an underwritten public offering of 12,310,000 shares of its common stock at a price to the public of $16.25 per share. All of the shares are being sold by Sangamo. The gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $200.0 million. The offering is expected to close on or about April 30, 2018, subject to customary closing conditions. In addition, Sangamo has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,846,500 shares of its common stock solely to cover overallotments at the public offering price, less the underwriting discounts and commissions.
- • On April 24, 2018, Sangamo Therapeutics announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. All of the shares are being offered by Sangamo. In addition, Sangamo expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $30.0 million of shares of its common stock solely to cover overallotments at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms of the offering. BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.
Therapeutic area: Rare diseases - Genetic diseases
Is general: Yes
